Table 2 Prevalence of Scabies - Before and After MDA
From: Mass drug administration for endemic scabies: a systematic review
Community Number | MDA Regimen | Author | Prevalence of Scabies Before MDA | Prevalence of Scabies After MDA | Community that Received MDA (%) | Prevalence Absolute reduction (%) | Prevalence Relative reduction (%) |
|---|---|---|---|---|---|---|---|
1 | Control | Bockarie et al. | 52.0% | 60.0% | n/a | −8.0% | −15.4% |
2 | Standard Care (control) | Romani et al. 2015 | 36.6% | 18.8% | n/a | 17.8% | 48.6% |
3 | BB Cream | Haar et al | 23.7% | 9.5% | 76.0% | 14.2% | 59.9% |
4 | Permethrin | Romani et al. 2015 | 41.8% | 15.8% | 85.0% | 26.0% | 62.2% |
5 | Permethrin | Andrews et al. | 16.1% | 12.7% | Not Reported | 3.4% | 21.1% |
6 | Permethrin | Carapentis et al. | 25.0% | 6.0% | Not Reported | 19.0% | 76.0% |
7 | Permethrin | Taplin et al. | 33.0% | 3.6% | 99.7% | 29.4% | 89.1% |
8 | IVM Two oral doses | Kearns et al. | 4.0% | 2.0% | 96.0% | 2.0% | 50.0% |
9 | IVM Two oral doses | Romani et al. 2019 | 18.7% | 2.3% | 99.0% | 16.4% | 87.7% |
10 | IVM Two oral doses | Lawrence et al. | 20.0% | 1.0% | 95.0% | 19.0% | 95.0% |
11 | IVM Single oral dose | Haar et al. | 37.9% | 20.0% | 49.0% | 17.9% | 31.1% |
12 | IVM Single oral dose | Bockarie et al. | 85.0% | 26.0% | 87.0% | 59.0% | 69.4% |
13 | IVM Single oral dose | Martin et al. | 4.4% | 0.8% | 85.0% | 3.6% | 80.9% |
14 | IVM Single oral dose | Marks et al. | 11.8% | 1.0% | 91.0% | 10.8% | 91.5% |
15 | IVM Single oral dose | Marks et al. | 9.2% | 0.7% | 91.0% | 8.5% | 92.4% |
16 | IVM Single oral dose | Romani et al. 2015 | 32.1% | 1.9% | 85.0% | 30.2% | 94.1% |
17 | IVM Single oral dose | Leppard & Naburi | 71.0% | 0.1% | 100.0% | 70.9% | 99.9% |
| Â | Â | Â | Â | Â | Average (Excluding Community 1&2) | 22.0% | 73.4% |
| Â | Â | Â | Â | Â | T-Test (p-value) | 0.0003 | Â |